Comment on “ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models”

Tesseur, Ina, Lo, Adrian C., Roberfroid, Anouk, Dietvorst, Sofie, Van Broeck, Bianca, Borgers, Marianne, Gijsen, Harrie, Moechars, Diederik +4 more·2013·Science
DOI 10.1126/science.1233937

Cited by (129)

Items 101–129 of 129

  1. Endogenous and combination retinoids are active in myelomonocytic leukemias
    Orsola di Martino, Haixia Niu, Gayla Hadwiger, Heikki A Kuusanmäki, Margaret A. Ferris, Anh Vu, Jeremy T. Beales, Carl E. Wagner, María Piedad Menéndez-Gutierrez, Mercedes Ricote et al. · 2020 · Haematologica
  2. A novel apoE-mimetic increases brain apoE levels, reduces Aβ pathology and improves memory when treated before onset of pathology in male mice that express APOE3
    Ana Carolina Valencia‐Olvera, Deebika Balu, Shreya Bellur, Thomas P. McNally, Yaseen Saleh, Don Pham, Shivesh Ghura, Jason M. York, Jan O. Johansson, Mary Jo LaDu et al. · 2023 · Alzheimer s Research & Therapy
  3. Bexarotene Impairs Cognition and Produces Hypothyroidism in a Mouse Model of Down Syndrome and Alzheimer’s Disease
    Verónica Vidal, A. Puente, Susana García-Cerro, M. T. García Unzueta, N. Rueda, J. Riancho, C. Martínez-Cué · 2021 · Frontiers in Pharmacology
  4. When the dust settles: what did we learn from the bexarotene discussion?
    Ina C. Tesseur, Bart De Strooper · 2013 · Alzheimer s Research & Therapy
  5. Bexarotene Binds to the Amyloid Precursor Protein Transmembrane Domain, Alters Its α-Helical Conformation, and Inhibits γ-Secretase Nonselectively in Liposomes
    Frits Kamp, Holger A. Scheidt, Edith Winkler, Gabriele Basset, Hannes Heinel, J.M.S. Hutchison, Loren M. LaPointe, Charles R. Sanders, Harald Steiner, Daniel Huster · 2018 · ACS Chemical Neuroscience
  6. Nuclear SphK2/S1P signaling is a key regulator of ApoE production and Aβ uptake in astrocytes
    Komai, Masato, Noda, Yuka, Ikeda, Atsuya, Kaneshiro, Nanaka, Kamikubo, Yuji, Sakurai, Takashi, Uehara, Takashi, Takasugi, Nobumasa · 2024 · Journal of Lipid Research
  7. Molecular dynamics simulations and molecular flooding studies of the retinoid X-receptor ligand binding domain
    Geoffrey M. Gray, Ning Ma, Carl E. Wagner, Arjan van der Vaart · 2017 · Journal of Molecular Modeling
  8. Relaunching an old drug: the potential role of bexarotene in neurodegenerative diseases
    Javier Riancho, Maria Teresa Berciano, José Berciano, Miguel Lafarga · 2016 · Journal of Neurology
  9. Effect of LXR/RXR agonism on brain and CSF Aβ40 levels in rats
    Songli Wang, Paul H. Wen, Stephen J. Wood · 2016 · F1000Research
  10. Brain metabolite clearance: impact on Alzheimer’s disease
    Juan Manuel Zolezzi, Nibaldo C. Inestrosa · 2014 · Metabolic Brain Disease
  11. Protective Effects of Bexarotene against Amyloid-β25-35-Induced Dysfunction in Hippocampal Neurons through the Insulin Signaling Pathway
    Weiwei Dai, Jiajia Yang, Ting Chen, Zhuo Ru Yang · 2014 · Neurodegenerative Diseases
  12. Inhibitory Mechanism of An Anticancer Drug, Bexarotene Against Amyloid β Peptide Aggregation: Repurposing Via Neuroinformatics Approach
    Nousheen Bibi, Syed Mohd Danish Rizvi, Abida Batool, Mohammad Amjad Kamal · 2019 · Current Pharmaceutical Design
  13. Early Treatment Critical: Bexarotene Reduces Amyloid-Beta Burden In Silico
    Joseph Rosenthal, Georges Belfort, David Isaacson · 2016 · PLoS ONE
  14. Cancer drugs with high repositioning potential for Alzheimer’s disease
    Jad Majeed, Marwan Noel Sabbagh, Min H. Kang, J. Josh Lawrence, Kevin Pruitt, Sarah S. Bacus, Ellie Reyna, Maddy Brown, Boris Decourt · 2023 · Expert Opinion on Emerging Drugs
  15. Therapeutic Strategies for Neurodegenerative Diseases
    Jacques Fantini, Nouara Yahi · 2015 · Elsevier eBooks
  16. Synthesis of a new fluorine-18-labeled bexarotene analogue for PET imaging of retinoid X receptor
    Min Wang, Toni Davis, Mingzhang Gao, Qi‐Huang Zheng · 2014 · Bioorganic & Medicinal Chemistry Letters
  17. Measuring Olfactory Processes in Mus musculus
    Heather Macintosh Schellinck · 2017 · Behavioural Processes
  18. Bexarotene cannot reduce amyloid beta plaques through inhibition of production of amyloid beta peptides: in silico and in vitro study
    Pham Dinh Quoc Huy, Nguyen Quoc Thai, Zuzana Bednáriková, Huynh Quang Linh, Zuzana Gažová, Mai Suan Li · 2018 · Physical Chemistry Chemical Physics
  19. The Impact of Apolipoprotein E Allelic Variants on Alzheimer’s Disease
    Ezequiel Serrano, Pablo G. Sanz, Francisco José Barrantes · 2021 · Springer eBooks
  20. Drug repurposing for neurodegenerative diseases
    Halak Shukla, Diana John, Shuvomoy Banerjee, Anand Krishna Tiwari · 2024 · Progress in molecular biology and translational science
  21. Perspectives on the Role of APOE4 as a Therapeutic Target for Alzheimer’s Disease
    Kavita Patel, Siwangi Srivastava, Shikha Kushwah, Ashutosh Mani · 2021 · Journal of Alzheimer s Disease Reports
  22. Pathogenesis, modulation, and therapy of Alzheimer’s disease: A perspective on roles of liver-X receptors
    Jasminka Štefulj, Ute Panzenboeck, Patrick R. Hof, Goran Šimić · 2013 · Translational Neuroscience
  23. Studies cast doubt on cancer drug as Alzheimer's treatment
    Helen M. Shen · 2013 · Nature
  24. Alzheimer’s Disease Therapeutics Targeting Apolipoprotein E
    Fan Liao, David M. Holtzman · 2016 · Elsevier eBooks
  25. Cerebral Innate Immunity
    David Gate, Terrence Town · 2016 · Elsevier eBooks
  26. The role of microglia in Alzheimer’s Disorder
    Xiaoyang Guo, Haishan Lan, Jin-Bin Liao · 2023 · Highlights in Science Engineering and Technology
  27. Impact de l’infection à Helicobacter pylori sur la maladie d’Alzheimer
    Claire Roubaud Baudron · 2014 · theses.fr (ABES)
  28. The role of the nicotinic receptors in prefrontal cortex spontaneous neuronal activity in the normal and diseased brain
    Fani Koukouli · 2016 · theses.fr (ABES)
  29. BindingDB Entry 50018264: Targeting Nuclear Receptors in Neurodegeneration and Neuroinflammation.
    BindingDB · 2024 · UC San Diego